Tonix Pharmaceuticals Holding (TNXP) Receivables (2023 - 2026)

Tonix Pharmaceuticals Holding has reported Receivables for 4 years, with the latest figure at $15.1 million in Q2 2026.

• On a quarterly basis, Receivables rose 246.42% year-over-year to $15.1 million in Q2 2026; TTM through Jun 2026 was $15.1 million, a 246.42% increase from a year earlier, with the FY2025 full-year figure at $9.8 million, up 110.44% from the prior year.
• Receivables was $15.1 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $12.2 million in the prior quarter.
• The five-year high for Receivables was $15.1 million in Q2 2026, with the low at $2.3 million in Q3 2023.
• Average Receivables over 4 years is $7.0 million, with a median of $5.1 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2026: Receivables tumbled 49.5% in 2024, then jumped 246.42% in 2026.
• Over 4 years, Receivables stood at $9.2 million in 2023, then slumped by 49.5% to $4.6 million in 2024, then jumped by 110.44% to $9.8 million in 2025, then jumped by 54.28% to $15.1 million in 2026.
• The last three Receivables figures came in at $15.1 million (Q2 2026), $12.2 million (Q1 2026), and $9.8 million (Q4 2025), per Business Quant data.